THIS WEEK IN THE PUBLIC INDEX
本週收錄 · AI 生物制藥與虛擬生命科學
2026-10-05 — 2026-10-09 · 北京時間週一 00:00 至頁面生成時的公開原文概要。
當前公開收錄 95 條
行業原文 51 條 · 精選期刊 AI 主題研究 44 條 · 有收錄的來源 14 個。
窗口起點 2026-10-04T16:00:00.000Z，生成時間 2026-10-09T07:45:21.141Z（UTC）；上方日期按北京時間展示。計數在列表限額之前計算，使用公開資源去重規則。撤銷來源或調整公開範圍後，計數和列表會重新計算。
主題為自動檢索分類，同一原文可進入多個主題。零表示當前收錄窗口沒有公開符合條件的條目，不表示行業沒有發生進展。
本週收錄的原文與出處
顯示最新 30 條，最多 30 條；完整統計為 95 條。每條直接連接本站記錄和原始出處。
Diffusing protein binders to intrinsically disordered proteins
Crossref REST API · 學術索引收錄 · 來源發佈：Wed Jul 30 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收錄：Fri Oct 09 2026 06:07:46 GMT+0000 (Coordinated Universal Time)
Abstract Proteins that bind to intrinsically disordered proteins (IDPs) and intrinsically disordered regions (IDRs) with high affinity and specificity could be useful for therapeutic and diagnostic applications 1–4 . How
Computational design of metallohydrolases
Crossref REST API · 學術索引收錄 · 來源發佈：Wed Dec 03 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收錄：Thu Oct 08 2026 11:07:46 GMT+0000 (Coordinated Universal Time)
Abstract De novo enzyme design seeks to build proteins containing ideal active sites with catalytic residues surrounding and stabilizing the transition state(s) of the target chemical reaction 1–7 . The generative artifi
AlphaFold ‘goes viral’: database adds protein complexes of common viruses
Crossref REST API · 學術索引收錄 · 來源發佈：Thu Sep 24 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收錄：Thu Oct 08 2026 11:07:46 GMT+0000 (Coordinated Universal Time)
AlphaFold ‘goes viral’: database adds protein complexes of common viruses
Sampling protein language models for functional protein design
Crossref REST API · 學術索引收錄 · 來源發佈：日期未提供 · 本站收錄：Thu Oct 08 2026 09:31:31 GMT+0000 (Coordinated Universal Time)
Sampling protein language models for functional protein design
Robust out-of-distribution prediction of Buchwald–Hartwig reactions
Crossref REST API · 學術索引收錄 · 來源發佈：Mon Aug 10 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收錄：Thu Oct 08 2026 09:29:04 GMT+0000 (Coordinated Universal Time)
Abstract The Buchwald–Hartwig cross-coupling is a cornerstone of modern pharmaceutical synthesis, yet predictive modeling of its outcomes remains constrained by data quality and chemical space coverage. Electronic labora
Multistate and functional protein design using RoseTTAFold sequence space diffusion
Crossref REST API · 學術索引收錄 · 來源發佈：Wed Sep 25 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收錄：Thu Oct 08 2026 09:21:33 GMT+0000 (Coordinated Universal Time)
Abstract Protein denoising diffusion probabilistic models are used for the de novo generation of protein backbones but are limited in their ability to guide generation of proteins with sequence-specific attributes and fu
Atomically accurate de novo design of antibodies with RFdiffusion
Crossref REST API · 學術索引收錄 · 來源發佈：Wed Nov 05 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收錄：Thu Oct 08 2026 09:15:50 GMT+0000 (Coordinated Universal Time)
Abstract Despite the central role of antibodies in modern medicine, no method currently exists to design novel, epitope-specific antibodies entirely in silico. Instead, antibody discovery currently relies on immunization
De novo designed proteins neutralize lethal snake venom toxins
Crossref REST API · 學術索引收錄 · 來源發佈：Wed Jan 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收錄：Thu Oct 08 2026 09:15:48 GMT+0000 (Coordinated Universal Time)
Abstract Snakebite envenoming remains a devastating and neglected tropical disease, claiming over 100,000 lives annually and causing severe complications and long-lasting disabilities for many more 1,2 . Three-finger tox
Engineering human multi-organ tissue chip niches for drug absorption, distribution, metabolism, excretion and toxicity prediction.
PubMed / NCBI E-utilities · 學術索引收錄 · 來源發佈：Mon Oct 05 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收錄：Thu Oct 08 2026 09:09:29 GMT+0000 (Coordinated Universal Time)
Predicting human drug responses in vitro remains a central challenge in drug development. Animal models have shown limited accuracy in recapitulating human drug absorption, distribution, metabolism, excretion and toxicit
Owkin to Integrate Kognitic's Clinical Trial Data Into K Pro Through New Collaboration
Owkin official newsroom · 行業原文收錄 · 來源發佈：Thu Aug 06 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收錄：Thu Oct 08 2026 09:09:24 GMT+0000 (Coordinated Universal Time)
NEW YORK & PARIS — Owkin, the agentic AI company pioneering Biological Artificial SuperIntelligence to revolutionize drug discovery and development, today announced a data collaboration with Kognitic to integrate Kogniti
Isomorphic Labs announces $600m external investment round
Isomorphic Labs official announcements · 行業原文收錄 · 來源發佈：Mon Mar 31 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收錄：Thu Oct 08 2026 09:09:23 GMT+0000 (Coordinated Universal Time)
Listen: Spotify Apple Podcasts Isomorphic Labs announces it has raised $600 Million in its first external funding round. The financing round is led by Thrive Capital, with participation from GV, and follow-on capital fro
CytoVI: deep generative modeling of antibody-based single cell data.
PubMed / NCBI E-utilities · 學術索引收錄 · 來源發佈：Wed Sep 30 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收錄：Thu Oct 08 2026 09:09:22 GMT+0000 (Coordinated Universal Time)
Antibody-based single-cell technologies, such as flow cytometry, mass cytometry and CITE-seq, have become widely used in clinical diagnostics and basic research; however, their analysis is complicated by technical noise,
FLIGHTED: Inferring fitness landscapes from noisy high-throughput experimental data.
PubMed / NCBI E-utilities · 學術索引收錄 · 來源發佈：Fri Oct 02 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收錄：Thu Oct 08 2026 09:09:22 GMT+0000 (Coordinated Universal Time)
Machine learning (ML) for protein design requires large protein fitness datasets generated by high-throughput experiments for training and benchmarking models. However, most models do not account for experimental noise i
Function-preserving watermarking of AI-generated proteins.
PubMed / NCBI E-utilities · 學術索引收錄 · 來源發佈：Wed Sep 30 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收錄：Thu Oct 08 2026 09:09:22 GMT+0000 (Coordinated Universal Time)
Generative artificial intelligence (AI) models are revolutionizing biology, with tools such as AlphaFold 3 and protein design models accelerating breakthroughs in protein structure prediction and the creation of new func
Owkin and CRO Aviano Sign Master Partnership Agreement to Foster Collaborative Oncology Research
Owkin official newsroom · 行業原文收錄 · 來源發佈：Fri Aug 07 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收錄：Thu Oct 08 2026 09:09:15 GMT+0000 (Coordinated Universal Time)
PARIS & PORDENONE, Italy — Owkin, the agentic AI company pioneering the first autonomous AI scientist to revolutionize drug discovery and development, and the Centro di Riferimento Oncologico di Aviano (CRO), a leading I
Isomorphic Labs appoints Dr. Ben Wolf as Chief Medical Officer and establishes US Presence
Isomorphic Labs official announcements · 行業原文收錄 · 來源發佈：Tue Jun 17 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收錄：Thu Oct 08 2026 09:09:05 GMT+0000 (Coordinated Universal Time)
Listen: Spotify Apple Podcasts Isomorphic Labs appoints Dr. Ben Wolf M.D., Ph.D., as Chief Medical Officer and establishes US Presence. Dr. Wolf will be based in the company's newly established Cambridge location, where
Owkin to License K Pro AI Scientist and Multimodal Oncology and Immunology Data to Boehringer Ingelheim
Owkin official newsroom · 行業原文收錄 · 來源發佈：Wed Sep 02 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收錄：Thu Oct 08 2026 09:08:56 GMT+0000 (Coordinated Universal Time)
NEW YORK & PARIS — Owkin, the agentic AI company striving to transform drug discovery and development for biopharma, today announced a license agreement with Boehringer Ingelheim for K Pro, Owkin’s AI Scientist, together
Isomorphic Labs to appoint Max Jaderberg as President
Isomorphic Labs official announcements · 行業原文收錄 · 來源發佈：Wed Nov 26 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收錄：Thu Oct 08 2026 09:08:54 GMT+0000 (Coordinated Universal Time)
Listen: Spotify Apple Podcasts Isomorphic Labs announces the appointment of Max Jaderberg as President of the company effective 1 January 2026, transitioning from his current role as Isomorphic Labs’ Chief AI Officer. Co
Owkin to License K Pro and Multimodal Data to Servier to Advance Oncology Research
Owkin official newsroom · 行業原文收錄 · 來源發佈：Fri Sep 11 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收錄：Thu Oct 08 2026 09:08:48 GMT+0000 (Coordinated Universal Time)
NEW YORK & PARIS - September 11, 2026 — Owkin, the agentic AI company pioneering the first automated AI scientist to revolutionize drug discovery and development, today announced an agreement with Servier, an independent
Iambic Named to CNBC Disruptor 50 for Second Consecutive Year
Iambic official newsroom · 行業原文收錄 · 來源發佈：Tue May 19 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收錄：Thu Oct 08 2026 09:08:47 GMT+0000 (Coordinated Universal Time)
San Diego, CA – May 19, 2026 – Iambic is a CNBC Disruptor 50 for the second year in a row, joining the ranks of repeat Disruptors OpenAI, AirBnB, and SpaceX. The Disruptor 50 is an annual list curated by CNBC to recogniz
Isomorphic Labs Enters into a Research Collaboration with Johnson & Johnson
Isomorphic Labs official announcements · 行業原文收錄 · 來源發佈：Tue Jan 20 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收錄：Thu Oct 08 2026 09:08:46 GMT+0000 (Coordinated Universal Time)
Listen: Spotify Apple Podcasts Isomorphic Labs announces a cross-modality, multi-target research collaboration with Johnson & Johnson. This partnership brings together Iso’s AI-first approach to drug discovery with Johns
Machine learning for functional protein design.
Europe PMC REST API · 學術索引收錄 · 來源發佈：Thu Feb 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收錄：Thu Oct 08 2026 09:08:43 GMT+0000 (Coordinated Universal Time)
Recent breakthroughs in AI coupled with the rapid accumulation of protein sequence and structure data have radically transformed computational protein design. New methods promise to escape the constraints of natural and
A Generative Neural Network for Maximizing Fitness and Diversity of Synthetic DNA and Protein Sequences.
Europe PMC REST API · 學術索引收錄 · 來源發佈：Thu Jun 25 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收錄：Thu Oct 08 2026 09:08:43 GMT+0000 (Coordinated Universal Time)
Engineering gene and protein sequences with defined functional properties is a major goal of synthetic biology. Deep neural network models, together with gradient ascent-style optimization, show promise for sequence desi
AI-enhanced adaptive virtual screening of large libraries for ligand discovery.
Europe PMC REST API · 學術索引收錄 · 來源發佈：Tue Sep 01 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收錄：Thu Oct 08 2026 09:08:43 GMT+0000 (Coordinated Universal Time)
Ultralarge virtual screenings (ULVSs) evaluate billions of molecules for drug discovery but face cost, flexibility and scalability limits. We introduce AdaptiveFlow, an open-source platform that makes ULVSs more accessib
Artificial intelligence for natural product drug discovery.
Europe PMC REST API · 學術索引收錄 · 來源發佈：Mon Sep 11 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收錄：Thu Oct 08 2026 09:08:43 GMT+0000 (Coordinated Universal Time)
Developments in computational omics technologies have provided new means to access the hidden diversity of natural products, unearthing new potential for drug discovery. In parallel, artificial intelligence approaches su
Owkin to Build AI Agents as Part of a Multi-Year K Pro License Agreement with AstraZeneca
Owkin official newsroom · 行業原文收錄 · 來源發佈：Wed May 13 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收錄：Thu Oct 08 2026 09:08:37 GMT+0000 (Coordinated Universal Time)
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to revolutionize drug discovery and development, today announced an agreement with AstraZeneca to build biopharma agents as part of their t
Bayer and Iambic collaborate to advance drug discovery with AI
Iambic official newsroom · 行業原文收錄 · 來源發佈：Mon Jun 22 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收錄：Thu Oct 08 2026 09:08:35 GMT+0000 (Coordinated Universal Time)
Bayer and Iambic collaborate to advance drug discovery with AI Collaboration focuses on small molecule discovery Bayer to leverage Iambic’s AI platform to address hard-to-drug targets Collaboration will strengthen Bayer’
Isomorphic Labs announces Series B investment round
Isomorphic Labs official announcements · 行業原文收錄 · 來源發佈：Tue May 12 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收錄：Thu Oct 08 2026 09:08:33 GMT+0000 (Coordinated Universal Time)
Listen: Spotify Apple Podcasts Isomorphic Labs announces it has raised $2.1 Billion in Series B funding. The financing round is led by Thrive Capital, and includes participation from existing backers Alphabet and GV alon
The Virtual Biotech: A multi-agent AI framework for therapeutic discovery and development.
PubMed / NCBI E-utilities · 學術索引收錄 · 來源發佈：Thu Sep 17 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收錄：Thu Oct 08 2026 09:08:33 GMT+0000 (Coordinated Universal Time)
Drug development requires evidence integration across biological scales and modalities, but relevant tools are fragmented. We introduce the Virtual Biotech, an organization of artificial intelligence (AI) agents modeled
Binding and sensing diverse small molecules using shape-complementary pseudocycles.
Europe PMC REST API · 學術索引收錄 · 來源發佈：Thu Jul 18 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收錄：Thu Oct 08 2026 09:08:29 GMT+0000 (Coordinated Universal Time)
We describe an approach for designing high-affinity small molecule-binding proteins poised for downstream sensing. We use deep learning-generated pseudocycles with repeating structural units surrounding central binding p
本週日期內的已核驗事件
3 條，顯示最多 10 條。優先按發生日期，缺失時按公告日期；此口徑與上方按收錄時間統計的原文不同。
Isomorphic Labs 加入 Virtual Biology Initiative
Wed Oct 07 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 1 條當前公開證據
据 Isomorphic Labs 官方公告，加入由 Biohub 召集的 Virtual Biology Initiative，参与组织将投入数据、计算与测量技术。Biohub 尚未完成本库实体归属核验，暂不绘制关系边。
晶泰公布 XGlue 分子胶平台与临床前管线进展
Tue Oct 06 2026 03:29:09 GMT+0000 (Coordinated Universal Time) · 1 條當前公開證據
据晶泰官方 RSS 中的公告，XGlue 工作结合计算与实验数据训练 AI 模型，对 E3 与目标蛋白组合进行优先级判断；不把公司表述转换为临床疗效证据。
Iambic 提交第二款自有 AI 发现候选药 IAM217 的 IND
Mon Oct 05 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 1 條當前公開證據
据 Iambic 官方公告，已提交 IAM217 的 IND 申请。提交申请不等于监管批准，也不代表临床疗效已获证实。
專題指南：從原文到判斷
按任務比較模型，按證據追蹤合作；每篇保留原始出處與更新日期。
虛擬細胞、AI 模型與公司：應該怎樣比較？
按輸入、輸出、任務和驗證條件比較單細胞模型、結構預測與蛋白設計，並區分模型論文與公司能力。
閱讀指南 · 更新 2026-10-08
AI 制藥公司合作時間線：從公告讀到證據
用真實官方公告區分合作主體、首付款、條件性里程碑和研發進度，並建立可追溯的合作時間線。
閱讀指南 · 更新 2026-10-08
每週 AI 制藥信息怎麼讀：公司動態、研究進展與覆蓋缺口
建立每週閱讀順序，分清公告、論文與臨床結果；理解本站本週收錄的時間窗口、分母和來源覆蓋。
閱讀指南 · 更新 2026-10-08